SeaStar Medical (NASDAQ:ICU) Stock Rating Upgraded by Wall Street Zen

SeaStar Medical (NASDAQ:ICU) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

A number of other brokerages have also weighed in on ICU. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of SeaStar Medical in a research note on Friday, July 17th. Maxim Group set a $8.00 price objective on shares of SeaStar Medical and gave the stock a “buy” rating in a research report on Thursday, May 14th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $8.00.

SeaStar Medical Price Performance

NASDAQ ICU opened at $3.18 on Friday. SeaStar Medical has a one year low of $2.07 and a one year high of $12.50. The firm has a market cap of $14.02 million, a P/E ratio of -0.81 and a beta of -1.05. The stock’s 50-day moving average is $3.66 and its 200-day moving average is $3.41.

SeaStar Medical (NASDAQ:ICU) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.91) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.97) by $0.06. SeaStar Medical had a negative return on equity of 162.75% and a negative net margin of 795.51%.The business had revenue of $0.61 million during the quarter, compared to analyst estimates of $0.49 million. Equities analysts anticipate that SeaStar Medical will post -3.58 EPS for the current year.

Hedge Funds Weigh In On SeaStar Medical

Large investors have recently bought and sold shares of the company. Millennium Management LLC bought a new position in shares of SeaStar Medical during the 3rd quarter worth approximately $102,000. Jane Street Group LLC bought a new stake in shares of SeaStar Medical in the fourth quarter worth $30,000. Finally, XTX Topco Ltd lifted its position in shares of SeaStar Medical by 395.4% in the second quarter. XTX Topco Ltd now owns 60,983 shares of the company’s stock worth $26,000 after purchasing an additional 48,674 shares in the last quarter. Institutional investors and hedge funds own 1.69% of the company’s stock.

About SeaStar Medical

SeaStar Medical, Inc (NASDAQ: ICU) is a medical device company focused on the development and commercialization of cerebral embolic protection systems for patients undergoing transcatheter aortic valve replacement (TAVR) procedures. The company’s mission is to reduce the risk of stroke and other neurologic events associated with structural heart interventions by capturing or deflecting embolic debris that can travel to the brain during catheter-based therapies.

The company’s flagship product, TriGUARD® 3, is a next-generation embolic deflection device designed to provide coverage of all three cerebral vessels during TAVR.